The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.

FDA approves Eli Lilly's weight loss drug to treat sleep apnea . Zepbound was approved to treat adults with moderate to severe obstructive sleep apnea. The FDA advised that the medication be used ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the ...

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea. The FDA’s decision may place added pressure on insurance companies to cover obesity ...

By Rachel Roubein and Daniel Gilbert. The Washington Post. The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...